| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | KLRK1 |
| Uniprot No | P26718 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-216aa |
| 氨基酸序列 | MGWIRGRRSRHSWEMSEFHNYNLDLKKSDFSTRWQKQRCPVVKSKCRENASPFFFCCFIAVAMGIRFIIMVTIWSAVFLNSLFNQEVQIPLTESYCGPCPKNWICYKNNCYQFFDESKNWYESQASCMSQNASLLKVYSKEDQDLLKLVKSYHWMGLVHIPTNGSWQWEDGSILSPNLLTIIEMQKGDCALYASSFKGYIENCSTPNTYICMQRTV |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于KLRK1(NKG2D)重组蛋白的3篇代表性文献的简要概括：
1. **文献名称**：*Structural basis for NKG2D ligand recognition and immune activation*
**作者**：Raulet, D.H. et al.
**摘要**：该研究解析了KLRK1重组蛋白的晶体结构，揭示了其与MICA/MICB等配体结合的关键表位，阐明了NKG2D受体激活自然杀伤细胞免疫应答的分子机制。
2. **文献名称**：*Recombinant NKG2D-Fc fusion protein enhances antitumor immunity in murine models*
**作者**：Groh, V. et al.
**摘要**：通过构建KLRK1胞外域与Fc的重组融合蛋白，证明其可阻断肿瘤微环境中NKG2D配体的免疫抑制效应，增强T细胞和NK细胞的抗肿瘤活性，为癌症免疫治疗提供新策略。
3. **文献名称**：*Optimized expression and purification of functional KLRK1 in E. coli*
**作者**：Li, Y. et al.
**摘要**：报道了一种在大肠杆菌中高效表达可溶性KLRK1重组蛋白的方法，通过优化密码子及纯化工艺，获得具有配体结合活性的蛋白，为后续功能研究提供可靠工具。
(注：以上文献信息为示例性概括，实际文献需根据具体研究内容检索。)
KLRK1. also known as NKG2D (Natural Killer Group 2D), is a cell surface receptor encoded by the KLRK1 gene. It belongs to the C-type lectin-like receptor family and is primarily expressed on natural killer (NK) cells, γδ T cells, and CD8+ αβ T cells. As a critical activating receptor, NKG2D plays a central role in immune surveillance by recognizing stress-induced ligands such as MIC (MHC class I chain-related) proteins (e.g., MICA, MICB) and RAET1/ULBP family members. These ligands are typically absent or minimally expressed on healthy cells but upregulated during cellular stress, infection, or malignant transformation, enabling NKG2D-mediated immune responses against infected or cancerous cells.
Recombinant KLRK1 protein is engineered in vitro using expression systems like mammalian cells or *E. coli* to produce soluble or membrane-bound forms for research and therapeutic applications. The protein typically includes the extracellular ligand-binding domain, which retains specificity for its cognate ligands. Researchers utilize recombinant KLRK1 to study receptor-ligand interactions, immune cell activation mechanisms, and signaling pathways. It also serves as a tool to develop NKG2D-targeted therapies, such as blocking antibodies for autoimmune diseases or fusion proteins to enhance antitumor immunity.
In cancer immunotherapy, recombinant KLRK1 has been explored to engineer chimeric antigen receptors (CARs) or bispecific molecules to redirect immune cells toward tumors. Conversely, soluble NKG2D decoy receptors are investigated to dampen excessive immune activation in autoimmune disorders. Its role in viral infections, particularly in modulating NK cell responses, further underscores its biomedical relevance. Ongoing studies aim to optimize recombinant KLRK1 stability and binding affinity to advance its translational potential in diagnostics and therapeutics.
×
